Fariha Shariq
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fariha Shariq has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Nadeem
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Eesha Khan Afridi
Jinnah Sindh Medical University, Karachi, Pakistan
2 shared publications - Ahmed Kunwer Naveed
Department of Medicine, Dow University of Health Sciences, Karachi
1 shared publication - Alexander Habte
Department of Surgery, Assab Military Hospital, Assab, Eritrea
1 shared publication - Ashna Habib
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
1 shared publication - Inshal Arshad Malik
Jinnah Sindh Medical University, Karachi, Pakistan
1 shared publication
Latest Publications
- Open Access
- 4 April 2024
- Published by Elsevier in World Neurosurgery: X
- Vol. 23, 100368
Comparing surgical outcomes: Craniotomy versus decompressive craniectomy in acute subdural hematoma - A systematic review and meta-analysis
- 4 April 2024
- Published by Elsevier in World Neurosurgery: X
- Vol. 23, 100368
Open AccessComparing surgical outcomes: Craniotomy versus decompressive craniectomy in acute subdural hematoma - A systematic review and meta-analysis
- Open Access
- 1 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (12) , 6067-6077
Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration
Geographic atrophy (GA) is a progressive form of age-related macular degeneration characterized by the degeneration of retinal pigment epithelial cells and photoreceptor death. The dysregulation of the complement cascade has been implicated in GA progression. This review provides a comprehensive overview of the pathophysiology of age-related macular degeneration and GA, discusses current therapeutic options, and focuses on the recent breakthrough drug, pegcetacoplan (SYFOVRE). Pegcetacoplan is a complement inhibitor that selectively targets the C3 complement protein, effectively modulating complement activation. Clinical trials, including the OAKS and DERBY studies, have demonstrated the efficacy of SYFOVRE in reducing the growth of GA lesions compared to placebo. The FDA approval of SYFOVRE as the first and only definitive therapy for GA marks a significant milestone in the management of this debilitating condition. The review also explores potential future treatment strategies, including immune-modulating agents and ocular gene therapy. While SYFOVRE offers new hope for GA patients, further research is needed to evaluate its long-term benefits, safety profile, and optimal treatment regimens.
- 1 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (12) , 6067-6077
Open AccessAdvancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration
Geographic atrophy (GA) is a progressive form of age-related macular degeneration characterized by the degeneration of retinal pigment epithelial cells and photoreceptor death. The dysregulation of the complement cascade has been implicated in GA progression. This review provides a comprehensive overview of the pathophysiology of age-related macular degeneration and GA, discusses current therapeutic options, and focuses on the recent breakthrough drug, pegcetacoplan (SYFOVRE). Pegcetacoplan is a complement inhibitor that selectively targets the C3 complement protein, effectively modulating complement activation. Clinical trials, including the OAKS and DERBY studies, have demonstrated the efficacy of SYFOVRE in reducing the growth of GA lesions compared to placebo. The FDA approval of SYFOVRE as the first and only definitive therapy for GA marks a significant milestone in the management of this debilitating condition. The review also explores potential future treatment strategies, including immune-modulating agents and ocular gene therapy. While SYFOVRE offers new hope for GA patients, further research is needed to evaluate its long-term benefits, safety profile, and optimal treatment regimens.